FierceBiotech18d
UPDATE: Biohaven's bipolar candidate fails to improve mania in pivotal trial
selective and self-administered immune therapy,” Chief Translational Officer Tova Gardin, M.D., said in the release. Biohaven’s stock dropped 14% Monday, sinking from $36.95 at market open to ...
Business Insider18d
Biohaven reports ‘positive’ data from study of BHV-1300
Tova Gardin, MD, MPP, Chief Translational Officer at Biohaven, commented, “BHV-1300 has demonstrated remarkable efficacy in deep lowering of total IgG, leveraging the groundbreaking technology ...
Morningstar18d
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
Tova Gardin, MD, MPP, Chief Translational Officer at Biohaven, commented, "BHV-1300 has demonstrated remarkable efficacy in deep lowering of total IgG, leveraging the groundbreaking technology of ...
Mena FN18d
Biohaven Reports Positive Degrader Data Achieving &Gt 80% Sustained Reductions In Total Igg With Potential First-In-Class BHV-1300
Tova Gardin, MD, MPP, Chief Translational Officer at Biohaven, commented, "BHV-1300 has demonstrated remarkable efficacy in deep lowering of total IgG, leveraging the groundbreaking technology of ...
Nasdaq18d
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new ... with Ypsomed AG. Dr. Gardin added, "This data released ...
Biohaven Ltd.: Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal ...